Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.

Abstract: The present invention concerns 4-amino-2-pyrido-bicyclic pyrimidines of Formula (I) that function as type II topoisomerase inhibitors and their use thereof as medicaments especially in the treatment of cancer. The invention also provides a method for the manufacture of 4-amino-2-pyrido bicyclic pyrimidines of Formula (I).

Abstract: An actuation device (1) comprising a threaded shaft (2) connected at one end to driving means adapted to allow the threaded shaft (2) to rotate about its longitudinal axis (a). A movable element (3) is provided with a cylindrical cavity (30) adapted to receive the threaded shaft (2), and configured so that a rotation of the threaded shaft (2) corresponds to a translation the movable element (3) along the longitudinal axis (a). The device (1) has two guiding rods (4,4?) coupled to the movable element (3) and adapted to constrain the translation of the latter along a direction parallel to the longitudinal axis (a). Element (3) comprises a first (31) and a second (32) element constrained to each other, wherein the first element (31) is coupled to the threaded shaft (2) and the second element (32) is coupled to the two guiding rods (4,4?).

Abstract: A display including: a plurality of light sources that emit light beams; a plurality of optical cores having an elongated shape, each optical core having a respective first end, which is optically coupled to a corresponding light source, each optical core further being such that the light beam emitted from the corresponding light source propagates in a guided manner inside the optical core; and a screen, each optical core having a respective second end, which is optically coupled to the screen. The display further includes an optical separation element, which forms a plurality of cavities that house corresponding optical cores, each cavity and the corresponding optical core forming a corresponding waveguide. The optical separation element absorbs visible light and laterally surrounds at least the first end of each optical core.

Abstract: Disclosed herein, inter alia, are compositions and methods for modulating the activity of N-acylethanolamine acid amidase for the treatment of a pathological state, including pain, an inflammatory condition, or a neurodegenerative disorder.

Abstract: The present invention relates to an epicyclic speed reducer (1), comprising a casing (4) comprising a first (2a) and a second opening (2b) arranged on opposite faces of said casing (4).

Abstract: A system for the exfoliation of a layered material is described, comprising in combination: an exfoliation station (14-22) operating on a volume of a dispersion of a layered precursor material, including a wet-jet milling device (10); and a collecting station (30, 40), located downstream of the exfoliation station (14-22), operating on a volume of a dispersion of the at least partly exfoliated material, in which the exfoliation station (14-22) and the collecting station (30, 40) are connected to each other through a fluid communication path (20) along which there are interposed flow regulating means (50) adapted to assume a first operating configuration in which the communication path (20) between the exfoliation station (14-22) and the collecting station (30, 40) is discontinued, where the exfoliation station (14-22) is adapted to subject a volume of dispersion of layered precursor material to a predetermined number of wet jet milling cycles; and a second operating configuration in which the communication pa

Abstract: The mechanism includes a threaded shaft extending along a longitudinal axis; a nut arranged coaxially with the threaded shaft; a plurality of rolling bearings interposed between the threaded shaft and the nut, each of the bearings comprising an outer race fixed to the nut, an inner race which is arranged coaxially with the outer race and is rotatable relative to the outer race about an axis of rotation, and a plurality of rolling members interposed between the outer race and the inner race; and a corresponding plurality of rings, each of which is fixed to the inner race of a respective bearing so as to rotate therewith about the same axis of rotation, and is interposed between the inner race of the bearing and the threaded shaft in such a manner that an inner surface of the ring is in contact with a screw thread of the threaded shaft.

Abstract: The present invention relates to substituted benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides substituted benzoxazolone derivatives for use in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.

Abstract: Globular microstructures comprising a liquid core and a solid shell that envelops the core comprising polymeric micro- or nanofibers, preferably obtained by electrospinning, comprising a hydrophobic polymer or a mixture of hydrophobic polymer with polymers derived from cellulose or with polyacrylates; the microstructures may have a further coating of nanoparticles or polymeric coating. The microstructures have applications similar to those of “liquid marbles” with improved mechanical properties.

Abstract: Process for producing a hydrophobic composite bioelastomer, comprising a cross-linked bioelastomer matrix in which an organic phase is dispersed, comprising the reaction of cross-linking of a hydroxyl-terminated polysiloxane with a silane coupling agent, comprising an acetoxysilane, to obtain a cross-linked polysiloxane with release of acetic acid. The reaction of cross-linking is carried out in the presence of starch to cause at least partial in situ acetylation by the acetic acid released from said starch that is incorporated in the cross-linked bioelastomer matrix.

Abstract: Composition in the form of a shaped device, for use as a fiducial marker in tissues in the animal body, in radiotherapy and/or radiosurgery, characterized in that it comprises:—a core consisting of a colloidal dispersion of metal nanoparticles and/or oxides or metal salts having X-ray-contrast properties, where said nanoparticles are stabilized with surfactants, polymers or capping agents in a liquid vehicle, and—a polymeric casing that encapsulates the core, said device having a minimum size of not less than 500 microns and a maximum size not greater than 3000 microns.

Abstract: A system includes an excavation assembly, which in turn includes a supporting body having a perimetric edge defining a closed path. A distribution apparatus protrudes transversally relative to the perimetric edge and is movable in a guided manner on the supporting body. The distribution apparatus transversally distributes a quantity of hardenable or solidifiable material towards the outside of the perimetric edge, so as to be able to lay a plurality of axially superimposed annular layers(s) of the hardenable or solidifiable material defining a tubular structure (T) around the excavation assembly. A motor device moves the distribution apparatus on the supporting body.

Abstract: Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.

Abstract: Described herein, inter alia, are compositions and methods useful for inhibiting fatty acid amide hydrolase.

Abstract: The present invention provides methods of making and using peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH). The present invention provides compounds and compositions that suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). The present invention also sets forth methods for inhibiting FAAH as well as methods for treating conditions such as, but not limited to, pain, inflammation, immune disorders, dermatitis, mucositis, the over reactivity of peripheral sensory neurons, neurodermatitis, and an overactive bladder. Accordingly, the invention also provides compounds, methods, and pharmaceutical compositions for treating conditions in which the selective inhibition of peripheral FAAH (as opposed to CNS FAAH) would be of benefit.

Abstract: Methods for the production of a biodegradable plastics material obtained from plant waste materials are provided which include the steps of dissolving plant waste material in an anhydrous solvent which includes anhydrous trifluoroacetic acid in order to dissolve a cellulose fraction of the material, the waste material being at least partly dehydrated in such a way that its water content is not likely to cause hydrolysis of the cellulose fraction, and removing the solvent from the solution containing the non-hydrolysed cellulose fraction.

Abstract: The present invention concerns, in a first aspect, compounds of Formula I as defined herein, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing such compounds. The present invention also relates to compounds of Formula I for use as acid ceramidase inhibitors, and in the treatment of cancer and other disorders in which modulation of the levels of ceramide is clinically relevant.

Abstract: An actuated joint comprising a first element and a second element movable one with respect to the other, a first actuator and a second actuator connected to said first and second element for controlling the movement of said joint in an agonist-antagonist way, wherein said first actuator has a nominal or maximum power greater than that of said second actuator and said second actuator comprises at least a first elastic element extendable so as to store a maximum amount of elastic energy greater than that storable by said first actuator.

Abstract: The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.